Searched for
BIOCON SHARES SURGE
West Bengal's electronics factory push; Fed jitters hit TCSWest Bengal is exploring ways to expand electronics manufacturing under EMC 2.0. This and more in today's ETtech Top 5.- Nifty stuck in a range but small and midcaps are where real money is being made: Ashish ChaturmohtaIndian stock markets may appear stagnant, but opportunities exist in small and midcap stocks. JM Financial's Ashish Chaturmohta highlights ...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Ahead of Market: 10 things that will decide D-Street action on MondayNifty broke below its 23,800–24,500 consolidation range, signalling near-term weakness, with resistance now seen at 23,800–24,000 and key s...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Stocks in news: TCS, HDFC Bank, ITC Hotels, Hyundai India, Adani EnterprisesMarkets surged for the fourth consecutive session, buoyed by favorable geopolitical cues. Key stocks like TCS, HDFC Bank, ITC Hotels, Hyund...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- Biocon shares surge 3% as subsidiary obtains USFDA approval for diabetes drugBiocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...
- Biocon shares in focus after CDSCO nod for diabetes drug LiraglutideBiocon shares are in focus as the company has received regulatory approval from the Central Drugs Standard Control Organisation for its dia...
- Biocon shares in focus as Q4 PAT soars 153% YoYBiocon shares: The company also reported consolidated revenue of Rs 4,454 crore, reflecting a 15% year-on-year increase on a like-for-like ...
- HSBC sees Biocon share price rallying up to Rs 430; stock surges 5%Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade reflects a turnaroun...
- Biocon shares surge over 4% after Malaysia unit gets clearance from the USFDABiocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed a...
- Biocon shares surge 5% after USFDA classifies Bengaluru site as VAIBiocon Share Price: Biocon shares surged 5.4% after FDA classified its Bengaluru facility as Voluntary Action Indicated (VAI). The stock is...
- Biocon shares surge 15%; brokerages upbeatBiocon rose 15%, closing at Rs 514, and the USFDA development sparked a revision of target price for its shares across brokerages.
- Biocon shares hit 2-week high post Q3 numbersConsolidated total income from operations also increased to Rs 1,044.4 crore for the quarter under review as against Rs 807.1 crore in the ...
- Biocon shares surge over 3% as EMA accepts review of biosimilar TrastuzumabTrastuzumab is used to treat certain breast and gastric cancers. At 11:05 am, shares of the company were trading at Rs 894 apiece, up 3.28%...
- Biocon shares gain over 5%, hit 52-week high intra-dayShares of biotechnology major Biocon today surged over 5 per cent after the company launched advanced novel therapy for the treatment of He...
- Stocks: The hits and missesReliance shares surged 4.7% to Rs 747.25 on short-covering after Kotak Securities maintained its buy rating on the stock.
Load More
